Trials / Completed
CompletedNCT03896581
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFα-IR) subjects with active Psoriatic Arthritis (PsA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Subjects will receive bimekizumab at pre-specified time-points. |
| OTHER | Placebo | Subjects will receive placebo at pre-specified time-points. |
Timeline
- Start date
- 2019-03-28
- Primary completion
- 2021-12-08
- Completion
- 2022-02-14
- First posted
- 2019-04-01
- Last updated
- 2026-01-28
- Results posted
- 2024-10-16
Locations
92 sites across 11 countries: United States, Australia, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Russia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03896581. Inclusion in this directory is not an endorsement.